Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 9/20 | 0.48 |
| ▸ | ACACA | Q13085 | 4/20 | 0.48 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18534331 | 0.91 | EPHX1 (0.52) | KMT2AEPHX1ACACBACACAPBK | |
| SCHEMBL19762295 | 0.88 | EPHX1 (0.50) | KMT2AEPHX1ACACBACACAPBK | |
| SCHEMBL4921002 | 0.88 | KMT2A (0.50) | KMT2AEPHX1ACACBACACAPBK | |
| SCHEMBL6154180 | 0.88 | KMT2A (0.50) | KMT2AEPHX1ACACBACACAPBK | |
| SCHEMBL4920988 | 0.88 | KMT2A (0.50) | KMT2AEPHX1ACACBACACAPBK | |
| Bicarbonate SCHEMBL1580718 | 0.87 | KMT2A (0.57) | KMT2AEPHX1ACACBACACADRD2 | |
| SCHEMBL4377073 | 0.87 | KMT2A (0.56) | KMT2AEPHX1ACACBACACADRD2 | |
| SCHEMBL3816616 | 0.87 | KMT2A (0.56) | KMT2AEPHX1ACACBACACADRD2 | |
| SCHEMBL3942686 | 0.87 | KMT2A (0.56) | KMT2AEPHX1ACACBACACADRD2 | |
| SCHEMBL190838 | 0.87 | KMT2A (0.56) | KMT2AEPHX1ACACBACACADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242609-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-12-02 | — | — | US | disclosed |
| EP-1246847-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | Synaptic Pharmaceutical Corporation (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2002002744-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242609-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | MCHR1, MCHR2, MC4R | KMT2A 1155/4885EPHX1 3185/4885ACACB 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.